Yan-jun Mi and Jing Gao contributed equally to this work.
Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma
Version of Record online: 16 NOV 2012
© 2012 Copyright the Authors. Journal compilation © 2012, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus
Diseases of the Esophagus
Volume 26, Issue 6, pages 636–643, August 2013
How to Cite
Mi, Y.-J., Gao, J., Xie, J.-D., Cao, J.-Y., Cui, S.-X., Gao, H.-J., Yao, S.-P., Liu, T., Zhang, Y.-Y., Guo, C.-H., Qiu, G.-Q. and Chen, Y.-Q. (2013), Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma. Diseases of the Esophagus, 26: 636–643. doi: 10.1111/dote.12002
- Issue online: 8 AUG 2013
- Version of Record online: 16 NOV 2012
- National Natural Science Foundation of China. Grant Number: 81101758
- Postdoctoral Science Foundation of China. Grant Number: 2012 M511514
- centromere protein F;
- esophageal cancer;
Centromere protein F (CENP-F), a cell cycle-regulated centromere protein, has been shown to affect numerous tumorigenic processes. This study aimed to clarify the prognostic significance of CENP-F expression in patients with esophageal squamous cell carcinoma (ESCC). The levels of CENP-F messenger RNA and protein were higher in ESCC cell lines than in the normal tissues. An immunohistochemical analysis of paired tissue specimens showed that the CENP-F expression was higher in tumorous tissues than in the adjacent non-tumorous tissues (P < 0.001). Moreover, there was a significant correlation between CENP-F expression and gender (P = 0.012), clinical stage (P = 0.039), and T classification (P = 0.026). Patients with higher CENP-F expression had shorter overall survival than those with lower CENP-F expression (P = 0.009). Multivariate Cox analysis indicated that CENP-F expression is an independent prognostic factor for overall survival (hazard ratio = 0.582, 95% confidence interval = 0.397–0.804, P = 0.041). Importantly, it was found that zoledronic acid (ZOL) could significantly enhance the chemotherapeutic sensitivity of ESCC cell lines with high CENP-F expression to cisplatin, although ZOL alone only exhibited a minor inhibitory effect to ESCC cells. In summary, these findings demonstrate that CENP-F may serve as a valuable molecular marker for predicting the prognosis of ESCC patients. In addition, the data indicate a potential benefit of combining ZOL with cisplatin in ESCC, suggesting that CENP-F expression may have therapeutic implications.